Looking to Bring Anti-epileptic Drug Testing Back In-House?
Product News Feb 21, 2013
Compatibility with most common clinical chemistry platforms, means no new equipment or specialist training is required, to introduce the ARK Diagnostics range of Anti-epileptic Drug Monitoring assays into users laboratory.
Measuring serum drug concentrations provides valuable information to aid clinical decisions about patient dose.
ARK Diagnostics immunoassays, for new generation drugs such as levetiracetam, lamotrigine, gabapentin, topiramate and zonisamide, are now available in the UK, exclusively from Alpha Laboratories.
These precise enzyme immunoassays are provided in a convenient ready-to-use format for easy automation.
Unaffected by common interfering substances such as rheumatoid factor, haemoglobin or triglycerides, these robust assays provide the sensitivity needed for clinical decisions.
With excellent correlation to traditional methods such as LC-MS/MS, HPLC and FPIA, the ARK AED assays can be run on most popular analyzers, including the Cobas c501 and Beckman AU640, enabling fast turn-around times.
Anti-epileptic drugs (AEDs) are often candidates for therapeutic drug monitoring and individualization of a dose is essential in epilepsy therapy.
However, identification of the optimal dose, on clinical grounds alone, can be a challenge, as AED treatment is prophylactic and occurrence of seizures sporadic.
Monitoring of serum concentrations helps optimize long-term seizure control and prevent toxicity.